Pathways of neurodegeneration in SBMA
Pathways of neurodegeneration in SBMA
批准号:
7351763
负责人:
Joseph Paul Taylor
金额:
$31.88万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2011-01-31
关键词:
AddressAffectAgeAndrogen ReceptorAndrogensAutophagocytosisBiological ModelsBrain StemCAG repeatCell DeathCellsClassificationDataDiseaseDisease ProgressionDrosophila genusEmployee StrikesEvaluationEventExonsGenderGeneticGoalsHereditary DiseaseHuntington DiseaseImpairmentIn VitroLengthLigand BindingLigandsLysosomesMediatingModelingMolecularMotor NeuronsMutationNerve DegenerationNeuronsNuclearOnset of illnessPathogenesisPathway interactionsPhosphorylation SitePlayPopulationPredispositionPropertyProteinsReceptor GeneResearch PersonnelRoleSiteSpecificitySpinal CordSpinobulbar Muscular AtrophySpinocerebellar AtaxiasSystemTestingToxic effectUbiquitinWorkbasedefined contributiondisease phenotypein vivomenmulticatalytic endopeptidase complexpolyglutamineprogramsprotein degradationreceptor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The long-term goal is to understand the molecular basis of spinobulbar muscular atrophy (SBMA) so that
treatment may be developed. SBMA is a hereditary disease characterized by progressive loss of motor
neurons in the brainstem and spinal cord. SBMA is caused by trinucleotide (CAG) repeat expansion in the
androgen receptor (AR) gene leading to polyglutamine expansion in AR protein. Eight other diseases have
the same kind of mutation: Huntington's disease, DRPLA, and six forms of spinocerebellar ataxia. Expanded
polyglutamine itself is toxic. However, despite widespread and overlapping expression of the disease
proteins, these disorders are distinguished by selective vulnerability of different populations of neurons. This
observation indicates that expanded polyglutamine cannot be the sole determinant of neurodegeneration.
The first aim of this proposal will address the role of discrete AR functional domains in the initiation and
pathogenesis of SBMA.
Another important determinant in the initiation and progression of polyglutamine disease is that status of the
cellular mechanisms responsible for protecting cells from toxic proteins. Two pathways of protein
degradation, the ubiquitin-proteasome system (UPS) and autophagy, have been implicated as playing
important roles in polyglutamine diseases. The UPS is a multi-component system that coordinates timely
and specific degradation of intracellular protein. Autophagy is a lysosome-mediated catabolic pathway and
is the primary means of bulk degradation of cytoplasmic components. In the second two aims of this
proposal, we will test specific hypotheses relating to the role of the UPS and autophagy in the pathogenesis
of SBMA.
Aim 1: Defining the contributions of specific AR domains to polyglutamine-expanded AR toxicity.
Aim 2: To test the hypothesis that SBMA pathogenesis is associated with impaired UPS
function in vivo.
Aim 3: To determine the role of autophagy in SBMA pathogenesis using histological and genetic approaches
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dynamic RNA-protein assemblies and neurological disease
-
批准号:10300049
-
项目类别:
-
资助金额:$89.75万
-
财政年份:2016
-
负责人:Joseph Paul Taylor
-
依托单位:
Dynamic RNA-protein assemblies and neurological disease
-
批准号:10063575
-
项目类别:
-
资助金额:$89.75万
-
财政年份:2016
-
负责人:Joseph Paul Taylor
-
依托单位:
Dynamic RNA-protein assemblies and neurological disease
-
批准号:9170202
-
项目类别:
-
资助金额:$89.75万
-
财政年份:2016
-
负责人:Joseph Paul Taylor
-
依托单位:
Dynamic RNA-protein assemblies and neurological disease
-
批准号:10518397
-
项目类别:
-
资助金额:$89.75万
-
财政年份:2016
-
负责人:Joseph Paul Taylor
-
依托单位:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
-
批准号:10242883
-
项目类别:
-
资助金额:$41.28万
-
财政年份:2014
-
负责人:Joseph Paul Taylor
-
依托单位:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
-
批准号:10473844
-
项目类别:
-
资助金额:$50.62万
-
财政年份:2014
-
负责人:Joseph Paul Taylor
-
依托单位:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
-
批准号:10020813
-
项目类别:
-
资助金额:$44.89万
-
财政年份:2014
-
负责人:Joseph Paul Taylor
-
依托单位:
Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Project Core #2
-
批准号:10687077
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2014
-
负责人:Joseph Paul Taylor
-
依托单位:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
-
批准号:8318723
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2008
-
负责人:Joseph Paul Taylor
-
依托单位:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
-
批准号:7917239
-
项目类别:
-
资助金额:$33.35万
-
财政年份:2008
-
负责人:Joseph Paul Taylor
-
依托单位:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
-
批准号:8127737
-
项目类别:
-
资助金额:$32.04万
-
财政年份:2008
-
负责人:Joseph Paul Taylor
-
依托单位:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
-
批准号:7527627
-
项目类别:
-
资助金额:$35.42万
-
财政年份:2008
-
负责人:Joseph Paul Taylor
-
依托单位:
HDAC6 and the intersection between the UPS, autophagy, and neurodegeneration
-
批准号:7683143
-
项目类别:
-
资助金额:$33.71万
-
财政年份:2008
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of Neurodegeneration in SBMA
-
批准号:8448750
-
项目类别:
-
资助金额:$36.94万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of Neurodegeneration in SBMA
-
批准号:8640212
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of Neurodegeneration in SBMA
-
批准号:8187742
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of neurodegeneration in SBMA
-
批准号:7555381
-
项目类别:
-
资助金额:$14.22万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of neurodegeneration in SBMA
-
批准号:7145959
-
项目类别:
-
资助金额:$34.0万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of neurodegeneration in SBMA
-
批准号:7228129
-
项目类别:
-
资助金额:$31.9万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
Pathways of neurodegeneration in SBMA
-
批准号:7904507
-
项目类别:
-
资助金额:$18.28万
-
财政年份:2006
-
负责人:Joseph Paul Taylor
-
依托单位:
海外基金